Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders ...

Edgewise Therapeutics , Inc. (NASDAQ:EWTX), with a market capitalization of $2.67 billion, is a biopharmaceutical company focused on developing innovative therapies for severe, rare muscle disorders.

In a report released yesterday, Leonid Timashev from RBC Capital maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report), with a price target of $56.00. The company’s shares ...

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) yesterday and set a price target of $50.00. The company’s shares closed yesterday at ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink ...

BOULDER, Colo., March 11, 2025--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten ...